<DOC>
	<DOC>NCT00856206</DOC>
	<brief_summary>The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are on urate-lowering therapy. Subjects will participate in this study for approximately 20 weeks. Rilonacept is being studied for use in preventing gout flares in subjects on urate-lowering therapy.</brief_summary>
	<brief_title>Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<criteria>Male or female 18 to 80 years of age Previously met the preliminary criteria of ARA for the classification of acute gout arthritis of primary gout Subjects with history of gout, initiating or currently on urate lowering therapy who are at risk of gout flare Acute gout flare within 2 weeks prior to the Screening Visit and during the screening visit Persistent chronic or active infections History of an allergic reaction to allopurinol History or presence of cancer within 5 years of the Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Metabolism, Inborn Errors</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Metabolic Disease</keyword>
	<keyword>Genetic Diseases, Inborn</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Metabolic disorder</keyword>
	<keyword>Purine Pyrimidine Metabolism, Inborn Errors</keyword>
	<keyword>Gout</keyword>
	<keyword>Intercritical Gout</keyword>
</DOC>